LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Autor:	Rorick-Kehn, Linda M., Witkin, Jeffrey M., Statnick, Michael A., Eberle, Elizabeth L., McKinzie, Jamie H., Kahl, Steven D., Forster, Beth M., Wong, Conrad J., Li, Xia, Crile, Robert S., Shaw, David B., Sahr, Allison E., Adams, Benjamin L., Quimby, Steven J., Diaz, Nuria, Jimenez, Alma, Pedregal, Concepcion, Mitch, Charles H., Knopp, Kelly L., Anderson, Wesley H., Cramer, Jeffrey W., McKinzie, David L.
Zdroj:	In Neuropharmacology February 2014 77:131-144
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect